Annual report
7634.TEDINET S100W5LL
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥15.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥14.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥13.8bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.3bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥994m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥1.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥24.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥23.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥21.2bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥20.3bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥19.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.9bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥5.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥18.7bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥17.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥15.6bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥14.5bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥13.5bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.0bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.7bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥8.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.3bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥5.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥745m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥690m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥64m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥740m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥903m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥958m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥937m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥469.18 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥450.7 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥402.98 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥358.33 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥313.14 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5,900.59 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,481.61 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,931.68 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,594.54 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,289.53 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 74.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.3% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.2% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.5% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.0% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 500 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 486 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 470 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 439 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 431 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥14.9bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥12.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥11.8bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥10.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥10.2bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.8bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥1.5bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.9bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.7bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.6bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.8bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.8bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.2bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.1bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥971m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥890m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥23.5bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥20.4bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥19.1bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥18.2bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥17.2bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.2bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥5.2bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥17.3bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥15.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥13.8bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥12.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥11.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥9.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥713.56 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥387.91 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥350.09 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥314.16 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥280.41 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥70 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥55 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥5,554.25 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,877.89 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,422.06 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,123.08 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,855.53 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 73.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.1% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 13.7% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 3,420,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,420,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,420,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,420,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 3,420,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 428 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 339 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 334 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 313 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 305 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 102
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥72m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥141m |
| Care Welfare Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥48m |
| Care Welfare Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥19m |
| Care Welfare Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Care Welfare Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Care Welfare Relatedreportable segment | segment assets | at 2025-03-31 | ¥350m |
| Care Welfare Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥44m |
| Home Medical Treatment Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥900m |
| Home Medical Treatment Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥592m |
| Home Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.7bn |
| Home Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.7bn |
| Home Medical Treatment Relatedreportable segment | segment assets | at 2025-03-31 | ¥2.6bn |
| Home Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥907m |
| Medical Gas Equipment Installation Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥22m |
| Medical Gas Equipment Installation Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥9m |
| Medical Gas Equipment Installation Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Medical Gas Equipment Installation Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Medical Gas Equipment Installation Relatedreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥86m |
| Medical Gas Equipment Installation Relatedreportable segment | segment assets | at 2025-03-31 | ¥284m |
| Medical Gas Equipment Installation Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥272m |
| Medical Gas Relatedreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥325m |
| Medical Gas Relatedreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥146m |
| Medical Gas Relatedreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Medical Gas Relatedreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Medical Gas Relatedreportable segment | segment assets | at 2025-03-31 | ¥1.7bn |
| Medical Gas Relatedreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥636m |
| Nursing Homereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥19m |
| Nursing Homereportable segment | employees | at 2025-03-31 | 42 pure |
| Nursing Homereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥331m |
| Nursing Homereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥331m |
| Nursing Homereportable segment | segment assets | at 2025-03-31 | ¥1.2bn |
| Nursing Homereportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥18m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥785m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥14.2bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥14.1bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥86m |
| —segment total | segment assets | at 2025-03-31 | ¥6.1bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥787m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥15.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥15.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥86m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥71m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥151m |
| Care Welfare Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥25m |
| Care Welfare Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥20m |
| Care Welfare Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| Care Welfare Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| Care Welfare Relatedreportable segment | segment assets | at 2024-03-31 | ¥351m |
| Care Welfare Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥40m |
| Home Medical Treatment Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥581m |
| Home Medical Treatment Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥673m |
| Home Medical Treatment Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥6.3bn |
| Home Medical Treatment Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥6.3bn |
| Home Medical Treatment Relatedreportable segment | segment assets | at 2024-03-31 | ¥2.3bn |
| Home Medical Treatment Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥800m |
| Medical Gas Equipment Installation Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥15m |
| Medical Gas Equipment Installation Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥9m |
| Medical Gas Equipment Installation Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| Medical Gas Equipment Installation Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| Medical Gas Equipment Installation Relatedreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥87m |
| Medical Gas Equipment Installation Relatedreportable segment | segment assets | at 2024-03-31 | ¥282m |
| Medical Gas Equipment Installation Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥344m |
| Medical Gas Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥176m |
| Medical Gas Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥142m |
| Medical Gas Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Medical Gas Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Medical Gas Relatedreportable segment | segment assets | at 2024-03-31 | ¥1.5bn |
| Medical Gas Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥609m |
| Nursing Homereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥19m |
| Nursing Homereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥350m |
| Nursing Homereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥350m |
| Nursing Homereportable segment | segment assets | at 2024-03-31 | ¥1.2bn |
| Nursing Homereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥17m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥797m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥863m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥13.8bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥13.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥87m |
| —segment total | segment assets | at 2024-03-31 | ¥5.6bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥800m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥865m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥14.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥14.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥87m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥5.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥2.0bn |
| Nursing Homereportable segment | employees | at 2025-03-31 | 42 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,581
| Item | Context | Value | Unit |
|---|---|---|---|
| Changes in scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and reasons for exclusion from scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Names of major unconsolidated subsidiaries and associates and reasons for not being accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding amounts of notes and accounts receivable trade and contract assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding promissory notes due on balance sheet date (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding shares and bonds etc of unconsolidated subsidiaries and associates (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of contract liabilities (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of revenue from contracts with customers (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding gain on sales of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding loss on disposal of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding reclassification adjustments income taxes and tax effects relating to other comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYearDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding amounts of assets and liabilities on finance lease transactions (text) | CurrentYearDuration | Text · Plus | |
| Notes leases consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes financial instruments consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes securities consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes retirement benefits consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes tax effect accounting consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes business combinations consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes revenue recognition consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Description of reportable segments (text) | CurrentYearDuration | Text · Plus | |
| Explanation of measurements of sales profit loss asset liability and other items for each reportable segment (text) | CurrentYearDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YearDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYearDuration | Text · Plus | |
| Description of nature and amounts of differences between reportable segments total and financial statements (text) | CurrentYearDuration | Text · Plus | |
| Information for each product or service (text) | Prior1YearDuration | Text · Plus | |
| Revenues from external customers information for each region (text) | Prior1YearDuration | Text · Plus | |
| Property plant and equipment information for each region (text) | Prior1YearDuration | Text · Plus | |
| Information for each of main customers (text) | Prior1YearDuration | Text · Plus | |
| Information for each product or service (text) | CurrentYearDuration | Text · Plus | |
| Revenues from external customers information for each region (text) | CurrentYearDuration | Text · Plus | |
| Property plant and equipment information for each region (text) | CurrentYearDuration | Text · Plus | |
| Information for each of main customers (text) | CurrentYearDuration | Text · Plus | |
| Description of factors which led to recognition of gain on bargain purchase (text) | CurrentYearDuration | Text · Plus | |
| Notes related parties consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes per share information consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes significant events after reporting period consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Annexed consolidated detailed schedule of corporate bonds (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |